Shield Therapeutics PLC | Ownership
Companies that own Shield Therapeutics PLC
JPMorgan Asset Management (UK) Ltd.
5,212,346
4.48%
-750,000
0%
05/31/2018
USS Investment Management Ltd.
5,101,000
4.38%
0
0.02%
08/02/2018
Hargreave Hale Ltd.
4,570,000
3.93%
-744,000
0.02%
08/02/2018
West Yorkshire Pension Fund
769,000
0.66%
0
0.01%
08/02/2018
Hargreaves Lansdown Stockbrokers Ltd.
754,000
0.65%
116,000
0%
08/02/2018
HSBC Bank Plc (Market-Maker)
551,000
0.47%
531,000
0.04%
08/02/2018
Peel Hunt LLP (Market-Maker)
428,000
0.37%
428,000
1.04%
08/02/2018
BlackRock Investment Management (UK) Ltd.
306,000
0.26%
-1,747,000
0%
08/02/2018
ERSTE-SPARINVEST Kapitalanlagegesellschaft mbH
302,000
0.26%
86,000
0%
08/02/2018
Hargreaves Lansdown Asset Management Ltd.
257,000
0.22%
94,000
0%
08/02/2018
| Address |
Northern Design Centre
Gatehead Quays GH NE8 3DF
United Kingdom
|
|
Employees
|
- |
| Website |
http://shieldtherapeutics.com |
| Updated |
07/08/2019 |
| Shield Therapeutics Plc is a pharmaceutical company. It engages in the development and commercialization of secondary care focused pharmaceuticals. Its products include Feraccru, which treats oral problems with iron deficiency anaemia; and PT20, which treats hyperphosphatemia. |
